19:51 , Apr 16, 2018 |  BC Extra  |  Preclinical News

Fate's CAR Ts show efficacy

Fate Therapeutics Inc. (NASDAQ:FATE) presented data Monday at the American Association for Cancer Research meeting in Chicago showing that its off-the-shelf CAR T cell therapy FT819 elicited an immune response in cell studies. FT819 cells...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
22:24 , Aug 11, 2017 |  BC Extra  |  Preclinical News

Study links FNAIT miscarriages to NK cells

In a paper published in Nature Communications , a team including scientists from St. Michael's Hospital and University of Toronto showed that NK cell activation leads to placental dysfunction and miscarriages in fetal/neonatal alloimmune thrombocytopenia...
20:32 , May 23, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Mouse studies suggest inhibiting FCGR2B and FCGR3 on macrophages could enhance effects of anti- PD-1 antibodies on tumors. In a xenograft mouse model of colorectal cancer treated with an anti-PD-1 antibody, intravital microscopy...
22:01 , Apr 7, 2017 |  BioCentury  |  Finance

Combo quest

By leading Viracta Therapeutics Inc. ’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal. Wicklow...
18:47 , Mar 17, 2017 |  BioCentury  |  Emerging Company Profile

B-ing persistent

Aleta Biotherapeutics Inc. is extending the use of CD19 -targeting CAR T cells by coating non-B cell tumors with the antigen. President and CSO Paul Rennert told BioCentury the key to effective CAR T cell...
07:00 , Aug 3, 2015 |  BioCentury  |  Finance

NK-ocking out cancer

Patrick Soon-Shiong is building what he hopes will be a suite of companies under the NantWorks LLC umbrella that together will help revolutionize cancer treatment. The latest is cancer immunotherapy company NantKwest Inc. (NASDAQ:NK), which...
07:00 , Jun 22, 2015 |  BioCentury  |  Emerging Company Profile

Singling out ovarian cancer

GamaMabs Pharma S.A. is developing a first-in-class mAb that has the potential to treat chemotherapy-resistant subtypes of ovarian cancer by activating phagocytosis in tumor-infiltrating immune cells and tethering them to tumor cells expressing a cancer-specific...
07:00 , Oct 27, 2014 |  BioCentury  |  Emerging Company Profile

Unum: Universal chimeras

Unum Therapeutics Inc. 's ACTR platform offers an approach for generating controllable T cell therapies that could be safer and applicable to a broader range of cancers than CAR- and TCR-based immunotherapies. The company debuted...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Clinical News

AFM13: Phase I data

An open-label, dose-escalation, U.S. and German Phase I trial in 28 patients with relapsed or refractory Hodgkin's lymphoma showed that AFM13 led to 2 partial responses and 14 cases of stable disease. Patients received 0.01-7...